Data Year:

For its 2025 fiscal year, KALARIS THERAPEUTICS INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Vikas Sinha
AlloVir's Former Chief Executive Officer, President and Chief Financial Officer
Total Compensation $1,100,954 View details Pay Rank By Title In Biotechnology industry #621 View more
Brett Hagen
Chief Accounting Officer and AlloVir's former Chief Accounting Officer
Total Compensation $1,439,174 View details Pay Rank By Title In Biotechnology industry #8 View more
Matthew Gall
Former Chief Financial Officer
Total Compensation $1,064,607 View details Pay Rank By Title In Biotechnology industry #365 View more
Andrew Oxtoby
President and Chief Executive Officer
Total Compensation $2,569,115 View details Pay Rank By Title In Biotechnology industry #405 View more
Matthew Feinsod
Chief Medical Officer
Total Compensation $1,673,771 View details Pay Rank By Title In Biotechnology industry #187 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at KALARIS THERAPEUTICS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. KALARIS THERAPEUTICS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. KALARIS THERAPEUTICS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Vikas Sinha
AlloVir's Former Chief Executive Officer, President and Chief Financial Officer
Total Cash $81,106 Equity $0 Other $1,019,848 $1,100,954
Brett Hagen
Chief Accounting Officer and AlloVir's former Chief Accounting Officer
Total Cash $586,627 Equity $295,417 Other $557,130 $1,439,174
Matthew Gall
Former Chief Financial Officer
Total Cash $115,328 Equity $949,279 Other $0 $1,064,607
Andrew Oxtoby
President and Chief Executive Officer
Total Cash $882,039 Equity $1,687,076 Other $0 $2,569,115
Matthew Feinsod
Chief Medical Officer
Total Cash $665,368 Equity $1,008,403 Other $0 $1,673,771
For its 2023 fiscal year, KALARIS THERAPEUTICS INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Ansbert Gadicke, M. D. Total Cash $7,333
David Hallal Total Cash $347,000
Derek Adams, Ph.D. Total Cash $408,593
Jeffrey S. Bornstein Total Cash $211,780
Juan Vera Total Cash $187,000
Malcolm Brenner, M.D., Ph.D. Total Cash $196,275
Morana Jovan-Embiricos, Ph.D. Total Cash $209,280
Shawn Tomasello Total Cash $200,731
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.